1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Improving sensitivity through data augmentation with synthetic lymph node metastases for AI-based analysis of PSMA PET-CT images
(
- Contribution to journal › Article
- 2023
-
Mark
PET/CT imaging 2 h after injection of [18F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h
(
- Contribution to journal › Article
- 2022
-
Mark
Biokinetics and dosimetry of 18F-PSMA-1007 in patients with prostate cancer
(
- Contribution to journal › Article
-
Mark
Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians
(
- Contribution to journal › Article
- 2021
-
Mark
Dose-reduced [18F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
(
- Contribution to journal › Article
-
Mark
Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy
(
- Contribution to journal › Article
- 2020
-
Mark
Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study
(
- Contribution to journal › Article
-
Mark
Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
(
- Contribution to journal › Article
- 2019
-
Mark
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
(
- Contribution to journal › Article
- 2018
-
Mark
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
(
- Contribution to journal › Article